London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Looks to be the JAK associations in the latest research, 27th March 2020!
Associations between immune-suppressive and stimulating drugs and novel COVID-19 a systematic review of current evidence
JAK inhibitors work by inhibiting the activity of one or more of the JAK family of enzymes, including, JAK1, JAK2, JAK3 and TYK3. JAKs interact with signal transducer and activator of transcription proteins (STATs) and the JAK-STAT pathway is central to cellular response to exogenous signals in the immune system. The JAK family of enzymes are responsible for signal transduction and JAK inhibitors play a major role in inhibiting and blocking cytokine release that can contribute to growth of malignant cells in cancer. JAK inhibitors are used in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis .
This review focuses on how the JAK-STAT pathway can be manipulated to reduce viral entry and inflammation in patients with coronavirus. The main targets that the review highlighted were baricitinib (JAK inhibitor), IRE1a (an endoplasmic reticulum stress sensor, leading to an increased expression of negative regulators of JAK-STAT SOCS1 and SOCS3) and combination therapies using tylophorine-based compounds with JAK2 inhibitors.
Current studies suggest that although there are potential targets in the JAK-STAT pathway that can be manipulated in the treatment for coronaviruses, they are all in early stages and require further in vitro and in vivo studies to confirm their therapeutic effects.
 - Jakinibs: A New Class of Kinase Inhibitors in Cancer and Autoimmune Disease
What we need to see is another compound, any compound, getting a trial without having human safety results in the bank, we haven't put ours in humans yet remember..be some big tape cutting to out straight into patients and kiss the healthy people out.. But it is strange times arm.
Thanks all. Something i had not considered. Trial rules will be relaxed. Aurora flt3 works but cant find a mtd. Relaxation?. Suspect tyk2 in a similar zone at the moment. I suspect some hurdles may be dropped if we have the promising compounds. Military /govt funding is reassuring to me
Looking like a no brainer for someone to trial our SDC-1801
Pfizer have their own similar TYK2/JAK1 in Phase 3 study’s so I don’t think that’s right guys!
I’ve noted that this site is monitored and when research appears here I appears as a tweet to up sentiment, it’s a PR company doing imo!
“Pfizer has established a leading kinase research capability with multiple unique kinase inhibitor therapies in development. ... PF-06700841: A tyrosine kinase 2(TYK2)/JAK1 inhibitor under investigation for the treatment of psoriasis, Crohn's disease, ulcerative colitis, vitiligo, and alopecia areata.”
The one that cannot be named o really :) off to do some digging in the garden and don't forget the formulation issues were only at higher doses / Happy Easter everyone and Stay Safe
Chinese Military scientists ordered to win the race.....
I thought we had "eyes on the Pfizer then.........."........?
now I am confused.......... :)
All the best (not a bad place to be :)
You may find this unbelievable but Midostaurin is sold in the US as Rydapt and the Manufacturer is......
Novartis Pharmaceuticals Corporation
Too much going on with SAR retweet’s and Norvartis connections with FLT3
This may be about to lift off......
Imhappy - where did you find that paper.......compound #2 (on page 12 of 31) is virtually identical to our FLT3. It is an approved AML oral drug called Midostaurin. Below is the paragraph from their findings. These researchers scanned over 1 million compounds from international drug databases and libraries and chose 9 compounds that they think could work against COVID-19
Number 2 is only a FLT3 which sounds very similar to Sareum’s FLT3 Aurora.
The Chinese must know this and this is way too coincidental. See below.
Compound 2. This compound is an approved drug, PKC412 (midostaurin, MW 570.6 g/mol) for the treatment of acute myeloid leukemia in adults with an FMS-like tyrosine kinase-3 (FLT3) mutation, as well as for the treatment of advanced systemic mastocytosis . The drug develop- ment journey of midostaurin was rather interesting, especially on account of its ability to interact with multiple targets including protein kinase C implicated in different solid tumors and B-cell malignancies, the angiogenic vascular endothelial growth factor involved in diabetic retinopathy, and FLT3 and KIT representing drug targets in FLT+ acute myeloid leukaemia and systemic mas- tocytosis for which it was eventually approved by the US Food and Drug Administration (FDA) and the European Medicines Agency . Similar to MK-3207, midostaurin is able to establish pro extensive contacts that are mostly hydrophobic in nature with the active site residues of M . Some of these contacts include S46, M49, H164, M165, E166, D187, R188, and Q189. Unlike MK 3207, midostaurin possesses a significantly rigid core composed of an eight-fused ring system and a relatively flexible acetamide-linked phenyl group. The linker amide is able to form a hydrogen bond with N162, which complements the hydrophobic interactions in other parts of that group. The pose of midostaurin in the active site allows for hydrophobic contacts with C145 and H41. It is also important to point out that midostaurin also features two amide bonds, one of which is a lactam,pro considering that proteins are the substrate of M .
I recently found a news article that stated the Chinese Communist Party had ordered its scientists to win the race............
Hi Coldfish compound 2 FLT3 caught my eye in the downloadable pdf / beyond my pay grade though
High throughput virtual screening to discover inhibitors of the main protease of the coronavirus SARS-CoV-2
Agree CFP - the lack of any news at the AGM, the admissions FLT3 Aurora was ‘shelved’, now a deal out of nowhere with an ‘unnamed’ listed Chinese Biotech.......is it really coincidental........
Time will tell......this looks like it could be our year.
I certainly would not rule out the chinese connection...even though they struggled with the formulation issue, hmbec would have a great knowledge of aurora and the timing of the deal is a big coincidence, especially when at the agm there was not a peep about any future development...could be a good call and when we find out who...a nice surprise.
How good would it be if we bagged 2 deals for covid and with the other stuff to come.....maybe gilead showing their hand!
Soz for the dot post.............!
LSE chat is still glitchy, and I've just proved a second post gets your original away........... :()
All the best (I fink.............. ! :)
eyes on the Pfizer then.......... :()
All the best (defo looking for a good outcome here, eventually :)
I have been a previous investor in SAR & got out without any loss.I recently dipped my toe in again with 75,000 shares & I am now at a paper loss but it is tempting to top up again on Tuesday morning and I suspect many others will also consider it.This could be SAR'S year for which many long termers then might get their just rewards.GLA & stay safe.
No way chesh, that deal was only penned a week ago..sar have tweeted it to highlight that collaborations are being done.
More interesting is the pfizer retweet, it could be that sar have submitted something to them or they have approached sar...they know all about our tyk2.
Then again, we could be getting well ahead of ourselves ofcourse....they know a lot better than us if they have something that could be effective and what would have to be done via the regulatory path so if its possible then we should be going all out for it and i hope they have made an approach to pfizer.....mind you, it would be even nicer if they approached us:)
Hi Imhappy - that is a great question, maybe there is some connection that the Chinese have seen with our FLT3 and COVID-19.
The below is taken from SARs website under the ‘other programmes’ tab, it mentions the autoimmune properties of FLT3 which links into the need to prevent the cytokine storms that have been reported in patients.
Sareum has used its SKIL platform to develop a novel chemical series that inhibits the activity of FLT3 kinase and is highly selective against a panel of other kinases. These have potential use against certain types of leukaemia as well as AUTOIMMUNE DISORDERS such as Rheumatoid Arthritis and Multiple Sclerosis.
Forgive me............ !
although SAR retweeted this Novartis news article, the article clearly states a collaboration with Incyte.
What am I missing here...........?
All the best (are we to steal the prize from Incyte............?)
I am a new investor here as only been in this for just over a year, I lost a fortune on MTFB and quite a lot here so I am loving the positivity . All you long term people seem knowledgeable about the compounds so I hope the new positivity pays off in this strange new world that we find ourselves.
Stoney - nice find, with reference to DoD - could there be a link with the delayed released of the SRI paper...whilst the lupus research predates the C19 situation, the researchers will be mindful of the potential.
‘ And again, the similarities between SARS-CoV-2 and SARS helps. “It looked enough like SARS that we had a bit of a head start,” says Amy Jenkins, a program manager at the Defense Advanced Research Projects Agency, the Pentagon’s blue-sky research arm, which is funding four different groups working on antibody therapy against the new virus.
The timing of the Chinese deal anyone seeing a connection FLT3 > Covid-19 >
I have taken my limit sells off. They were at a quid. Im not a known ramper. 4 quid possibly but a very big spectrum inbetween. **** all to zillionnnaire. But we place our own bets. Mine is sar
Hi all - just read this article on Endpoints from ‘Atlantic’ with insights in how to fight the proteins linked to COVID-19. It mentions the cytokine storms that have been discussed elsewhere. All interesting finds and for sure there is a mega race on now to develop not only treatment but also the vaccine
I am very excited by this potential covid avenue. No doubt there must be some wind in the sail because as JonT suggested when things get to the nitty gritty the c..wombles turn up and lo and behold some signs appear. All I can say is that Novacyt are a diagnostics business and there shareprice has gone from a low of 0.06p in Oct last year and hit £5.17 yesterday- Sar on the other hand potentially have the molecules to create vaccines. So can you imagine the impact it would have here.- The FDA et all are cutting redtape and fasttracks are becoming supertracks. As Thoth says a very exciting few months to look forward to and if we are best in class then trials will be superfast.